adam10

INCB3619 is a selective and potent inhibitor of ADAM with antitumour effects, inhibiting ADAM10, ADAM17, MMP12 and MMP15.

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.

GI254023X is a MMP9 and ADAM10 inhibitor with IC50 values ​​of 2.5 and 5.3 nM, respectively. GI254023X can also significantly inhibit the proliferation of Jurkat cells and induce apoptosis.

GW280264X (Carbamic acid) is an inhibitor of ADAM17 .

Anti-Human/Mouse/Bovine ADAM10 Antibody (8C7) is a monoclonal antibody targeting human, mouse and bovine ADAM10 and can be used in signal transduction research.

P2X1 receptor antagonist

TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer.

KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).

Aderbasib (INCB007839) is an orally active and potent ADAM10 and ADAM17 inhibitor with antitumor activity, used for studying cancer and cardiovascular diseases.

Anti-MICB Antibody is a humanized monoclonal antibody targeting MHC class I polypeptide-related sequence B (MICB). MICB is a critical ligand for the activating receptor NKG2D expressed on NK cells and CD8+ T cells. Tumor cells often evade immune surveillance by proteolytically shedding MICB via proteases (e.g., ADAM10/17), leading to reduced surface ligand density. This antibody typically binds to the α3 domain of MICB, specifically inhibiting its proteolytic shedding and stabilizing MICB expression on the tumor cell surface. This process restores NKG2D-mediated immune recognition and enhances the cytotoxic activity of NK cells and T cells against tumors, serving as a vital tool for researching tumor immune evasion mechanisms and developing novel immunotherapies.